The drugmaker announced plans to discontinue a phase three trial for the shot in a March 29 press release, describing the decision as “part of a broader effort to make strategic choices for its pipeline and research and development investments to focus on medicines with the greatest potential benefit to patients.”
Johnson & Johnson first launched the phase three trial in September 2021, which involved about 23,000 adults aged 60 and older.
Meanwhile, several other drugmakers, including Pfizer, are pushing ahead with plans to gain FDA approval for their RSV vaccine candidates. There is currently no approved vaccine for the disease.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.